

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Eduardo N. MITRANI et al

Serial No.: 10/519,838

Filed: 08-Dec-2005

For: METHOD AND DEVICES FOR INDUCING
BIOLOGICAL PROCESSES BY MICRO-ORGANS

Examiner: KIM, TAEYOON



§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1651

Attorney
Docket: 28888

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Martin D. Moynihan
Registration No. 40,338

Dated: November 27, 2006



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/519,838
Filing Date	08-Dec-2005
First Named Inventor	MITRANI Eduardo N. et al
Art Unit	1651
Examiner Name	KIM, TAEYOON
Attorney Docket Number	28888

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Foreign Patent Documents						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/519,838	
			Filing Date	08-Dec-2005	
			First Named Inventor	MITRANI Eduardo N. et al	
			Group Art Unit	1651	
			Examiner Name	KIM, TAEYOON	
Sheet	2	Of	3	Attorney Docket Number	28888
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	2	Lyons et al. "Vgr-1, A Mammalian Gene Related to Xenopus Vg-1, Is A Member of the Transforming Growth Factor ? Gene Superfamily", Proc. Natl. Acad. Sci. USA, 86: 4554-4558, 1989.			
	3	Bullough et al. "The Control of Epidermal Mitotic Activity in the Mouse", Proceedings of the Royal Society, Series B., Biological Sciences, 151(945): 517-536, 1960. Abstract.			
	4	Albano et al. "A Mesoderm-Inducing Factor Produced by WEHI-3 Murine Myelomonocytic Leukemia Cells Is Activin A", Development, 110: 435-443, 1990.			
	5	Schubert et al. "Activin Is A Nerve Cell Survival Molecule", Nature, 344: 868-870, 1990. Abstract.			
	6	Smith et al. "Identification of A Potent Xenopus Mesoderm-Inducing Factor as A Hologue of Activin A", Nature, 345: 729-731, 1990. Abstract.			
	7	Asashima et al. "Mesodermal Induction in Early Amphibian Embryos by Activin A (Erythroid Differentiation Factor)", Development Genes and Evolution, 198(6): 330-335, 1990. Abstract.			
	8	Mason et al. "Complementary DNA Sequences of Ovarian Follicular Fluid Inhibin Show Precursor Structure and Homology With Transforming Growth Factor-Beta", Nature, 318: 659-663, 1985. Abstract.			
	9	Ling et al. "Pituitary FSH Is Released by A Heterodimer of the Beta-Subunits From the Two Forms of Inhibin", Nature, 321: 779-782, 1986. Abstract.			
	10	Vale et al. "Purification and Characterization of An FSH Releasing Protein From Porcine Ovarian Follicular Fluid", Nature, 321: 776-779, 1986. Abstract.			
	11	Thomsen et al. "Activins Are Expressed Early in Xenopus Embryo-Genesis and Can Induce Axial Mesoderm and Anterior Structures", Cell, 63: 485-493, 1990. Abstract.			
	12	Jones et al. "Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in Morphogenesis and Neurogenesis in the Mouse", Development, 111: 531-542, 1991.			
	13	Mitrani et al. "Induction by Soluble Factors of Organized Axial Structures in Chick Epiblasts", Science, 247: 1092-1094, 1990. Abstract.			
	14	Mitrani et al. "Activin Can Induce the Formation of Axial Structures and Is Expressed in the Hypoblast of the Chick", Cell, 63: 495-501, 1990. Abstract.			
	15	Weiss et al. "A Model of Growth & Growth Control in Mathematical Terms", The Journal of General Physiology, 41(1): 1-47, 1957.			
	16	Murata et al. "Erythroid Differentiation Factor Is Encoded by the Same mRNA as That of the Inhibin Beta A Chain", Proc. Natl. Acad. Sci. USA, 85: 2434-2438, 1988.			
Signature		Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/519,838
				Filing Date	08-Dec-2005
				First Named Inventor	MITRANI Eduardo N. et al
				Group Art Unit	1651
				Examiner Name	KIM, TAEYOON
Sheet	3	Of	3	Attorney Docket Number	28888
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
	17	Thompson et al. "Expression of Transforming Growth Factor-Beta1 in Specific Cells and Tissues of Adult and Neonatal Mice", The Journal of Cell Biology, 108: 661-669, 1989.			
	18	Pelton et al. "Expression of Transforming Growth Factor Beta 2 RNA During Murine Embryogenesis", Development, 106(4): 759-767, 1989. Abstract.			
	19	Mathews et al. "Expression Cloning of An Activin Receptor, A Predicted Transmembrane Serine Kinase", Cell, 65: 973-982, 1991. Abstract.			
	20	Cassell et al. "Vascularisation of Tissue-Engineered Grafts: The Regulation of Angiogenesis in Reconstructive Surgery and in Disease States", British Journal of Plastic Surgery, 55: 603-610, 2002.			
	21	Khurana et al. "Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism", Hypertension, 38(5): 1210-1216, 2001.			
	22	Laham et al. "Gene Transfer for Angiogenesis in Coronary Artery Disease", Annual Reviews in Medicine, 52: 485-502, 2001.			
	23	Tran et al. "Autologous Cell Transplantation and Cardiac Tissue Engineering: Potential Applications in Heart Failure", Biorheology, 40(1-3): 411-415, 2003. Abstract.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.